News and Stories

November 30, 2023

Everything You Need to Know About HIV Testing

Whether you are sexually active or just want to stay informed, being aware of your HIV status is an important step in taking charge of your sexual health. 

Read More
November 10, 2023

Unveiling the World of Genetic Counseling: An Interview with Elizabeth Melchionna

In honor of Genetic Counselor Awareness Day, we had the privilege of speaking with Elizabeth Melchionna, a genetic counselor at HNL Lab Medicine. 

Read More
November 06, 2023

Gut Check: Clostridium difficile

Clostridioides difficile, commonly known as C. diff, is a bacterium that can cause infections in the colon, leading to a range of symptoms that can be uncomfortable and, in some cases, serious.

Read More
November 03, 2023

Celebrating Our Commitment to Quality: Recent CAP Inspection Validates HNL Lab Medicine’s Excellence

At HNL Lab Medicine, we are thrilled to share a significant milestone that exemplifies our commitment to delivering exceptional quality healthcare.

Read More
October 29, 2023

World Stroke Day

Sharing a Personal Experience on World Stroke Day to Raise Awareness about Strokes.

Read More
News and Stories

January 03, 2023

Myeloid malignancies are clonal diseases with multiple known genetic mutations. Genomic sequencing is advantageous in the classification and treatment of these diseases and can now be performed with a single test. Along with deep sequencing, this myeloid assay accesses the comprehensive oncology knowledgebase and broadens treatment options by linking relevant diseases and locating available clinical trials. This new in-house assay delivers prompt results and complements HNL Genomics offerings.

New NGS Myeloid Panel Information

The Oncomine myeloid assay uses Next Generation Sequencing (NGS) to detect variants in 40 key DNA target genes and 29 driver fusion genes. Using the comprehensive oncology knowledgebase, variants are linked to relevant FDA approved therapy options, disease guidelines, and global clinical trials.

This targeted DNA and fusion panel detects DNA mutations and fusion transcripts associated with major myeloid disorders: acute myeloid leukemia (AML), myeloid dysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), and juvenile myelomonocytic leukemia (JMML).

Benefits of NGS Myeloid Panel

Precision medicine is just one test away. The Oncomine myeloid assay profiles myeloid malignancies with a single test. Save your patients the time and costs associated with multiple sequential tests. Even challenging targets such as CEBPA and internal tandem duplications of FLT3 (FLT3-ITDs) are detected.

The comprehensive knowledgebase locates clinical trials and provides the answers you need to develop personalized treatment plans for your patients. Additionally, this assay can be performed with blood or bone marrow specimens, offering the flexibility your patients need.

Our genetic testing experts are available to assist with any questions. Unlike the frequently delayed results from competitors, our in-house testing delivers seamless turnaround. The turnaround time for our Oncomine myeloid assay is 10-14 days; FLT3-ITDs and TKD results are reported in just 2-3 days. Results are available in EPIC.

Epic Orderable of NGS Myeloid Panel

To improve accessibility and ease of order, providers suspecting myeloid malignancies can order this test easily in EPIC. Check out our Lab Handbook (linked here for details.

Our genetic testing experts are available to assist with any questions. Results will be available in EPIC as well.

Test Summary of NGS Myeloid Panel

  • Oncomine Myeloid Assay
  • 40 key DNA target genes and 29 fusion genes
  • Turnaround time: 10-14 days

Time matters to your patients. HNL Lab Medicine delivers patient results quickly and conveniently. For clinical information or to discuss a patient, providers may contact HNL Genomics at 877-402-4221.